According to preliminary statistics of its financial department, Zhongyuan Union Stem Cell Bio-engineering Corporation predicts a net profit owned by shareholders in 2014 to be not less than RMB 36 million after excluding extraordinary profit and loss, with earnings per share being not less than RMB 0.10 after excluding extraordinary profit and loss.
Vcanbio Cell & Gene Engineering Corp., Ltd
Equities
600645
CNE000000545
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.08 CNY | +0.89% | -0.70% | -15.74% |
1st Jan change | Capi. | |
---|---|---|
-15.74% | 107.86Cr | |
-2.58% | 811.11Cr | |
+7.73% | 566.85Cr | |
+29.76% | 561.92Cr | |
-15.77% | 388.54Cr | |
+12.42% | 268.04Cr | |
-61.85% | 258.33Cr | |
-5.50% | 226.23Cr | |
+23.09% | 203.37Cr | |
-9.25% | 181.66Cr |
- Stock Market
- Equities
- 600645 Stock
- News Vcanbio Cell & Gene Engineering Corp., Ltd
- Zhongyuan Union Stem Cell Bio-Engineering Corporation Provides Earnings Guidance for the Year 2014